Big Pharma Insiders Pessimistic About Pricing Going Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Pricing and market access continue to be trends that plague big pharma, even as patent expirations and lagging new drug launches create harder circumstances for companies.
You may also be interested in...
German Pricing Mechanism Adds Weak Economies, Could Spell Trouble For EU Industry
The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.